Gowers Review of Intellectual Property

Golden Tag Shares to Resume Trading and Provides Update to Its Acquisition of the La Parrilla Silver Mine Complex

Retrieved on: 
Friday, April 14, 2023

TORONTO, April 14, 2023 (GLOBE NEWSWIRE) -- Golden Tag Resources Ltd. (“Golden Tag” or the "Company") (TSX.V: GOG) is pleased to provide the following update regarding its proposed acquisition of the La Parrilla Silver Mine Complex (“La Parrilla”) in Durango, Mexico (the “Transaction”) from First Majestic Silver Corp (“First Majestic”) pursuant to an asset purchase agreement entered into between First Majestic, First Majestic Plata, S.A. DE C.V., and Golden Tag, dated December 7, 2022 (the “Asset Purchase Agreement”) and as previously announced in the Company’s news release dated December 7, 2022. Upon dissemination of this news release, the Company anticipates trading will resume in the Golden Tag Shares (as defined herein) on or about April 19, 2023.

Key Points: 
  • Upon dissemination of this news release, the Company anticipates trading will resume in the Golden Tag Shares (as defined herein) on or about April 19, 2023.
  • In accordance with the policies of the TSXV, trading in the Golden Tag Shares has remained halted in connection with the proposed Transaction announced on December 7, 2023.
  • The Company expects that trading will resume on or about April 19, 2023, following the dissemination of this press release and subject to approval from the TSXV.
  • On April 14, 2023, Golden Tag closed a further tranche of its previously announced non-brokered private placement of subscription receipts (the “Offering”).

Self-amplifying RNA (saRNA or Replicons) Vaccines Patent Landscape Report 2023 with IP Profiles of Key Players - AlphaVax, BioNTech, Gritstone bio, GSK, Janssen, Merck - Animal Health, & Novartis - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 30, 2023

The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Self-amplifying RNA vaccines Patent Landscape Analysis 2023" report has been added to ResearchAndMarkets.com's offering.
  • Currently, there are 2 main types of mRNA vaccines: conventional non-amplifying mRNA and self-amplifying mRNA (saRNA or replicons).
  • The saRNA vaccine platform may have higher manufacturing productivity and lower cost per dose compared to mRNA vaccines.
  • Moreover, this innovative and less expensive therapy tends to apply to the veterinary area with treatments for companion animals and livestock.

Katten Intellectual Property Group Grows With Advertising Litigator

Retrieved on: 
Wednesday, October 26, 2022

WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Katten announced today that Christopher Cole has joined the Washington, DC office as a partner in the Intellectual Property (IP) department where he will chair the Advertising, Marketing and Promotions practice group, bolstering the firm's profile in advertising law.

Key Points: 
  • WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Katten announced today that Christopher Cole has joined the Washington, DC office as a partner in the Intellectual Property (IP) department where he will chair the Advertising, Marketing and Promotions practice group, bolstering the firm's profile in advertising law.
  • The practical and innovative approach Chris brings as a talented advertising litigator in solving cutting-edge IP issues strengthens our department's capabilities to serve our high-profile roster of clients in this ever-evolving, competitive landscape," said Deepro R. Mukerjee, chair of Katten's global Intellectual Property department.
  • Cole's practice focuses on advertising, unfair competition, brand disparagement, reputation and intellectual property matters.
  • In his new role at Katten, Cole will lead the Intellectual Property department's Advertising, Marketing and Promotions practice group in guiding advertisers, advertising and promotions agencies, technology developers, content producers and entertainment companies through litigation, counseling and transactions.

Randal Heeb Joins FTI Consulting as a Senior Managing Director in the Economic Consulting Segment

Retrieved on: 
Monday, March 14, 2022

WASHINGTON, March 14, 2022 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Dr. Randal Heeb as a Senior Managing Director in the firms Economic Consulting segment.

Key Points: 
  • WASHINGTON, March 14, 2022 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Dr. Randal Heeb as a Senior Managing Director in the firms Economic Consulting segment.
  • At FTI Consulting, Dr. Heeb will lead the Litigation and Dispute Resolution practice within the Economic Consulting segment, expanding FTI Consultings capabilities in intellectual property and antitrust disputes, both in litigation and alternative dispute resolution (ADR) settings.
  • FTI Consulting delivers sophisticated economic analysis of issues arising in M&A transactions, antitrust litigation, commercial disputes, international arbitrations, regulatory proceedings, IP disputes and a wide range of financial litigation, said Mark McCall , Head of the North American Economic Consulting segment at FTI Consulting.
  • Dr. Heeb joins FTI Consulting from Bates White Economic Consulting, where he led the Intellectual Property practice and co-led the Antitrust and Competition practice.